文章：

肝门部胆管癌的多学科综合治疗：指南回顾与最新进展

Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements

原文发布日期：20 December 2023

DOI: 10.3390/cancers16010030

类型: Article

开放获取: 是

英文摘要：

Cholangiocarcinoma (CCA) is a rare malignancy of the intrahepatic and extrahepatic biliary ducts. CCA is primarily defined by its anatomic location: intrahepatic cholangiocarcinoma versus extrahepatic cholangiocarcinoma. Hilar cholangiocarcinoma (HC) is a subtype of extrahepatic cholangiocarcinoma that arises from the common hepatic bile duct and can extend to the right and/or left hepatic bile ducts. Upfront surgery with adjuvant capecitabine is the standard of care for patients who present with early disease and the only curative therapy. Unfortunately, most patients present with locally advanced or metastatic disease and must rely on systemic therapy as their primary treatment. However, even with current systemic therapy, survival is still poor. As such, research is focused on developing targeted therapies and multimodal strategies to improve overall prognosis. This review discusses the work-up and management of HC focused on the most up-to-date literature and ongoing clinical trials.

摘要翻译： 

胆管癌（CCA）是一种罕见的肝内及肝外胆管恶性肿瘤。其分类主要依据解剖位置：肝内胆管癌与肝外胆管癌。肝门部胆管癌（HC）是肝外胆管癌的一种亚型，起源于肝总管并可延伸至右肝管和/或左肝管。对于早期患者，根治性手术联合卡培他滨辅助治疗是标准治疗方案，也是目前唯一可能实现治愈的方法。遗憾的是，多数患者就诊时已处于局部进展期或发生转移，必须依赖全身性治疗作为主要治疗手段。然而，即使采用当前最先进的全身治疗方案，患者生存率仍然较低。因此，当前研究重点聚焦于开发靶向治疗及多模式综合治疗策略以改善总体预后。本综述基于最新文献及正在进行中的临床试验，系统探讨肝门部胆管癌的诊疗策略。

原文链接：

Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements